213 related articles for article (PubMed ID: 32006898)
21. All-trans retinoic acid enhances the cytotoxic effect of decitabine on myelodysplastic syndromes and acute myeloid leukaemia by activating the RARα-Nrf2 complex.
Wang L; Zhang Q; Ye L; Ye X; Yang W; Zhang H; Zhou X; Ren Y; Ma L; Zhang X; Mei C; Xu G; Li K; Luo Y; Jiang L; Lin P; Zhu S; Lang W; Wang Y; Shen C; Han Y; Liu X; Yang H; Lu C; Sun J; Jin J; Tong H
Br J Cancer; 2023 Feb; 128(4):691-701. PubMed ID: 36482192
[TBL] [Abstract][Full Text] [Related]
22. [The Effects of Decitabine Combined with All-Trans Retinoic Acid on the Number of Immune Cells in Myeloid Neoplasms].
Wei W; Liu Y; Shang LM; Cao Y; Wang F; Guo YT; Lin RR; Lin Y; Dong WM; Gu WY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):6-11. PubMed ID: 35123596
[TBL] [Abstract][Full Text] [Related]
23. Abnormal regulation of miR-29b-ID1 signaling is involved in the process of decitabine resistance in leukemia cells.
Ma J; Wen X; Xu Z; Xia P; Jin Y; Lin J; Qian J
Cell Cycle; 2023 May; 22(10):1215-1231. PubMed ID: 37032592
[TBL] [Abstract][Full Text] [Related]
24. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
25. DNA methylation landscape reveals GNAS as a decitabine-responsive marker in patients with acute myeloid leukemia.
He S; Li Y; Wang L; Li Y; Xu L; Cai D; Zhou J; Yu L
Neoplasia; 2024 Mar; 49():100965. PubMed ID: 38245923
[TBL] [Abstract][Full Text] [Related]
26. Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia.
Fabiani E; Leone G; Giachelia M; D'alo' F; Greco M; Criscuolo M; Guidi F; Rutella S; Hohaus S; Voso MT
Leuk Lymphoma; 2010 Dec; 51(12):2275-84. PubMed ID: 21077739
[TBL] [Abstract][Full Text] [Related]
27. A critical role of epigenetic inactivation of miR-9 in EVI1
Mittal N; Li L; Sheng Y; Hu C; Li F; Zhu T; Qiao X; Qian Z
Mol Cancer; 2019 Feb; 18(1):30. PubMed ID: 30813931
[TBL] [Abstract][Full Text] [Related]
28. Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid Malignancies.
Tayari MM; Santos HGD; Kwon D; Bradley TJ; Thomassen A; Chen C; Dinh Y; Perez A; Zelent A; Morey L; Cimmino L; Shiekhattar R; Swords RT; Watts JM
Clin Cancer Res; 2021 Apr; 27(7):1893-1903. PubMed ID: 33495312
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.
Ye XN; Zhou XP; Wei JY; Xu GX; Li Y; Mao LP; Huang J; Ren YL; Mei C; Wang JH; Lou YJ; Ma LY; Yu WJ; Ye L; Xie LL; Luo YW; Hu C; Niu LM; Dou MH; Jin J; Tong HY
Leuk Lymphoma; 2016; 57(6):1311-8. PubMed ID: 26372888
[TBL] [Abstract][Full Text] [Related]
30. Decitabine Versus Intensive Chemotherapy for Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia.
Choi EJ; Lee JH; Park HS; Lee JH; Seol M; Lee YS; Kang YA; Jeon M; Woo JM; Lee KH
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):290-299.e3. PubMed ID: 30879987
[TBL] [Abstract][Full Text] [Related]
31. Decitabine and SAHA-induced apoptosis is accompanied by survivin downregulation and potentiated by ATRA in p53-deficient cells.
Brodská B; Otevřelová P; Holoubek A
Oxid Med Cell Longev; 2014; 2014():165303. PubMed ID: 25140197
[TBL] [Abstract][Full Text] [Related]
32. Decitabine induces very early in vivo DNA methylation changes in blasts from patients with acute myeloid leukemia.
Claus R; Pfeifer D; Almstedt M; Zucknick M; Hackanson B; Plass C; Lübbert M
Leuk Res; 2013 Feb; 37(2):190-6. PubMed ID: 23158571
[TBL] [Abstract][Full Text] [Related]
33. Genomic impact of transient low-dose decitabine treatment on primary AML cells.
Klco JM; Spencer DH; Lamprecht TL; Sarkaria SM; Wylie T; Magrini V; Hundal J; Walker J; Varghese N; Erdmann-Gilmore P; Lichti CF; Meyer MR; Townsend RR; Wilson RK; Mardis ER; Ley TJ
Blood; 2013 Feb; 121(9):1633-43. PubMed ID: 23297133
[TBL] [Abstract][Full Text] [Related]
34. Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment.
Yabushita T; Chinen T; Nishiyama A; Asada S; Shimura R; Isobe T; Yamamoto K; Sato N; Enomoto Y; Tanaka Y; Fukuyama T; Satoh H; Kato K; Saitoh K; Ishikawa T; Soga T; Nannya Y; Fukagawa T; Nakanishi M; Kitagawa D; Kitamura T; Goyama S
Cell Rep; 2023 Sep; 42(9):113098. PubMed ID: 37714156
[TBL] [Abstract][Full Text] [Related]
35. Real-world experience with decitabine as a first-line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy.
Bocchia M; Candoni A; Borlenghi E; Defina M; Filì C; Cattaneo C; Sammartano V; Fanin R; Sciumè M; Sicuranza A; Imbergamo S; Riva M; Fracchiolla N; Latagliata R; Caizzi E; Mazziotta F; Alunni G; Di Bona E; Crugnola M; Rossi M; Consoli U; Fontanelli G; Greco G; Nadali G; Rotondo F; Todisco E; Bigazzi C; Capochiani E; Molteni A; Bernardi M; Fumagalli M; Rondoni M; Scappini B; Ermacora A; Simonetti F; Gottardi M; Lambertenghi Deliliers D; Michieli M; Basilico C; Galeone C; Pelucchi C; Rossi G
Hematol Oncol; 2019 Oct; 37(4):447-455. PubMed ID: 31385337
[TBL] [Abstract][Full Text] [Related]
36. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial.
Short NJ; Kantarjian HM; Loghavi S; Huang X; Qiao W; Borthakur G; Kadia TM; Daver N; Ohanian M; Dinardo CD; Estrov Z; Kanagal-Shamanna R; Maiti A; Benton CB; Bose P; Alvarado Y; Jabbour E; Kornblau SM; Pemmaraju N; Jain N; Gasior Y; Richie MA; Pierce S; Cortes J; Konopleva M; Garcia-Manero G; Ravandi F
Lancet Haematol; 2019 Jan; 6(1):e29-e37. PubMed ID: 30545576
[TBL] [Abstract][Full Text] [Related]
37. miR-15a/16-1 enhances retinoic acid-mediated differentiation of leukemic cells and is up-regulated by retinoic acid.
Gao SM; Yang J; Chen C; Zhang S; Xing CY; Li H; Wu J; Jiang L
Leuk Lymphoma; 2011 Dec; 52(12):2365-71. PubMed ID: 21838537
[TBL] [Abstract][Full Text] [Related]
38. Decitabine as a First-Line Treatment for Older Adults Newly Diagnosed with Acute Myeloid Leukemia.
Park H; Chung H; Lee J; Jang J; Kim Y; Kim SJ; Kim JS; Min YH; Cheong JW
Yonsei Med J; 2017 Jan; 58(1):35-42. PubMed ID: 27873493
[TBL] [Abstract][Full Text] [Related]
39. Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort.
Stahl M; DeVeaux M; Montesinos P; Itzykson R; Ritchie EK; Sekeres MA; Barnard JD; Podoltsev NA; Brunner AM; Komrokji RS; Bhatt VR; Al-Kali A; Cluzeau T; Santini V; Fathi AT; Roboz GJ; Fenaux P; Litzow MR; Perreault S; Kim TK; Prebet T; Vey N; Verma V; Germing U; Bergua JM; Serrano J; Gore SD; Zeidan AM
Blood Adv; 2018 Apr; 2(8):923-932. PubMed ID: 29685952
[TBL] [Abstract][Full Text] [Related]
40. miR-133a and miR-135a Regulate All-Trans Retinoic Acid-Mediated Differentiation in Pediatric Acute Myeloid Leukemia by Inhibiting CDX2 Translation and Serve as Prognostic Biomarkers.
Cheng YC; Fan Z; Liang C; Peng CJ; Li Y; Wang LN; Luo JS; Zhang XL; Liu Y; Zhang LD
Technol Cancer Res Treat; 2024; 23():15330338241248576. PubMed ID: 38693824
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]